Loos, a professor at the University of Copenhagen and affiliated with a research center supported by the Novo Nordisk Foundation (the maker of Wegovy and Ozempic), noted, "The current model explains only 25% of the variability, and further research is needed to uncover the remaining 75%." However, she also expressed optimism, stating, "By combining genetic and clinical information, the era of personalized medicine, where we can select the best drug for each patient, may be upon us."
However, results vary and depend on overall health, training, and nutrition
Signs Your Body Is Not Handling Heat Properly Most people ignore early symptoms
Nrf2: an all-rounder in depression
Ward JD, Barnes CG, Fisher DJ, Jessop JD, Baker RW: Improvement in nerve conduction following treatment in newly diagnosed diabetics
Bei Medikamenten, die nicht von uns verordnet wurden, ist eine persnliche Rcksprache in unserer Arztpraxis erforderlich